Stalicla, uma startup genebrina, recorre a algoritmos para definir perfil biológico de cada grupo de autistas e, assim, identificar fármacos mais eficazes. O ensaio clínico do primeiro pacote terapêutico da empresa aguarda luz verde da agência reguladora de medicamentos dos Estados Unidos.
STALICLA SA’s CEO Lynn Durham joined a panel of leading industry experts at the SACHS European Life Sciences CEO Forum on February 25th-26th, 2019 in Zurich, Switzerland. The ‘Neuroscience BD&L’ panel which Lynn was part of, took place at 11:20am Monday 25th.
STALICLA is pleased to announce the successful closure of the 2018 tranche of its series A round for a total amount of CHF 10M committed by a consortium of private and Biotech experienced investors
STALICLA CEO, Lynn Durham presents STALICLA’s most recent biomarker data at the 2nd Annual Neuroscience Innovation Forum in San Francisco